Insulin glargine and incidence of cancer - An ongoing debate

Journal of Diabetes Science and Technology

Volumn 4, Issue 2, 2010, Pages 497-498

  Hermanns, Norbert ^a   Kulzer, Bernd ^a  

^a Research Institute of the Diabetes Academy Mergentheim   (Germany)

Author keywords

Cancer; Diabetes; Insulin glargine; Insulin therapy; Neutral protamine Hagedorn insulin

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; INSULIN;

CHEMICALLY INDUCED DISORDER; DIABETES MELLITUS; DOSE RESPONSE; HUMAN; LETTER; NEOPLASM; REGISTER; REPRODUCIBILITY; RISK FACTOR;

DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NEOPLASMS; REGISTRIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 77955477385     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400235     Document Type: Letter

References (6)

1. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52(9):1732-44.
2. Gale EA. Insulin glargine and cancer: another side to the story? Lancet. 2009;374(9689):521.
3. Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet. 2009;374(9689):511-3.
4. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia. 2009;52(12):2499-506.
5. Rosenstock J, Fonseca V, McGill JB, Riddle M, Hallé JP, Hramiak I, Johnston P, Davis M. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia. 2009;52(9):1971-3.
6. Garg SK, Hirsch IB, Skyler JS. Insulin glargine and cancer - an unsubstantiated allegation. Diabetes Technol Ther. 2009;11(8):473-6.